Plus, news about PepGen and Jasper Therapeutics:
Jazz Pharmaceuticals buys Redx Pharma’s KRAS inhibitors: The company is paying Redx $10 million upfront, with milestones up to $870 million. The deal will extend Redx’s runway into 2025.
Alto Neuroscience’s upsized IPO: The Los Altos-based CNS biotech raised $147.9 million in its initial public offering, selling 9.2 million shares at $16.00 each.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.